Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Eli Lilly is making waves by acquiring SiteOne Therapeutics for up to $1 billion, eyeing a non-opioid chronic pain treatment.

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

NRG's Stock Is a Top Gainer. How Does It Really Make Money? The company looks more like a risky energy trader than a simple power producer. Ethan Allen Faces Fewer Tariffs Than Rivals, but Consumer ...

The agreement unites two brands that are popular with Gen Z and helps the buyer diversify its supply chain outside of China. Pipeline operator Williams will seek to build two natural-gas supply lines ...

Swiss President Karin Keller-Sutter will visit pharma powerhouse Ireland tomorrow for high-level talks ahead of President ...

Amid rising geopolitical tensions, persistent inflation concerns, and growing skepticism about long-term fiscal discipline, investors increasingly seek stability in hard assets. The U.S. national debt ...